Pharmacy Times

JULY 19, 2025

Signal Transduction Targeted Therapy 2020; 5:101. HALO: results from a phase 2 double-blind, placebo-controlled trail evaluating the efficacy and safety of baxdrostat in patients with uncontrolled hypertension. Presented at ACC/WCC 2023. March 4, 2023. New Orleans. Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art.

HIV Treatment and Prevention Agents 25

HIV Treatment and Prevention Agents Pharmacy Technician Compounding Pharmacies Pharmacy Management 25

Pharmacy Times

JULY 25, 2025

Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis, and Treatment of Lyme Disease. Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Arthritis Care Res ( Hoboken ). 2021;73(1):1-9.

HIV Treatment and Prevention Agents 26

HIV Treatment and Prevention Agents Pharmacy Technician Insurance Coverage and Processing Department of Veterans Affairs 26

Pharmacy Times

JUNE 9, 2025

trillion economic impact in 2020. trillion economic impact in 2020. trillion (about $4600 per capita in the US) in 2020. trillion in 2020. LIMITX technology, developed by Abuse Deterrent Pharma and Acura Pharmaceuticals, controls drug release to reduce overdose risk. It just might start saving lives. REFERENCES 1.

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Compounding Pharmacy Management 29

Pharmacy Times

JULY 22, 2025

While the European Medicines Agency mandated pre-treatment DPD testing in Europe as early as 2020, and the UK’s National Health Service followed suit the same year, the US only reached a consensus in 2025. Pharmacists’ involvement in these areas is crucial, from patient education and dose adjustment to monitoring outcomes. 1991;68(3):499-501.

Pharmacy Technician 20

Pharmacy Technician Insurance Coverage and Processing Compounding Pharmacies Diabetes 20

Pharmacy Times

JUNE 16, 2025

The first one was introduced on September 13, 2020, near the end of Trump’s first term, but was shut down by a federal judge due to the administration’s failure to comply with the proper implementation processes. September 13, 2020. Trump to pitch sweeping Medicare drug price plan. May 7, 2025. Accessed May 13, 2025.

Pharmacy Technician 26

Pharmacy Technician Drug Pricing Insurance Coverage and Processing Compounding Pharmacies 26

Pharmacy Times

JULY 24, 2025

Patients with ankylosing spondylitis may be able to receive the same benefits as reference adalimumab (Humira; AbbVie) at a lower cost by using IBI303 (Innovent Biologics), a biosimilar, wrote authors of research published in Medicine (Baltimore).

Biosimilars 26

Biosimilars Pharmacy Technician Compounding Pharmacies Hospitals 26

Pharmacy Times

JULY 2, 2025

On February 21, 2020, the FDA approved eptinezumab-jjmr (Vyepti; Lundbeck) as the first intravenous migraine preventative treatment for adults. Pharmacists are essential in managing access, patient education, and monitoring outcomes, ensuring adherence and addressing administrative challenges.

Pharmacy Technician 52

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunization 52

Putting Patients First Blog

JUNE 26, 2025

CMS should draw on lessons from previous transitions, including biosimilar coverage rollouts and site-of-care policy shifts, to avoid known implementation pitfalls. Report to the Congress: Medicare and the Health Care Delivery System , June 2020. AMA Journal of Ethics 24, no. Washington, DC: MedPAC. April 14, 2023.

Drug Pricing 52

Drug Pricing Communication Drug Development Documentation 52

Pharmacy Times

JULY 28, 2025

VMAT2 Inhibitors Updated in 2020, American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia (Third Edition) and A Modified Delphi Consensus Study of the Screening, Diagnosis, and Treatment of Tardive Dyskinesia recommend treatment with a VMAT2 inhibitor for patients with TD. Ment Health Clin.

Pharmacy Technician 26

Pharmacy Technician Diabetes Compounding Pharmacies Compounding 26

Pharmacy Times

JUNE 25, 2025

Updated January 22, 2020. months versus 7.79 months with tislelizumab. A study of TQB2450 or placebo combined with anlotinib, etoposide and carboplatin versus etoposide and carboplatin in subjects with extensive small cell lung cancer (ETER701). Accessed June 25, 2025.

Chemotherapy 20

Chemotherapy Pharmacy Technician Immunization Diabetes 20

Pharmacy Times

JULY 15, 2025

Since launching Amazon Pharmacy in November of 2020, we've made it easier for patients to access low-priced medications and have them delivered to their door. Common barriers that I think of include access and cost, but also treatment complexity and forgetfulness.

Pharmacy Technician 26

Pharmacy Technician Diabetes Biosimilars Compounding Pharmacies 26

pharmaphorum

JUNE 20, 2025

Skip to main content Friday 20 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 72

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 72

Pharmacy Times

JULY 8, 2025

Anti-TNFs remain the only FDA-approved class for pediatric IBD, prompting biosimilar use for cost and accessibility. Anti-TNFs remain the only FDA-approved class for pediatric IBD, prompting biosimilar use for cost and accessibility. SHOW MORE The study found biosimilar initiation rose to nearly 42% from 2016 to 2023.

Biosimilars 40

Biosimilars HIV Treatment and Prevention Agents Pharmacy Technician Compounding Pharmacies 40

Pharmacy Times

JULY 18, 2025

Updated May 6, 2020. Finerenone and the Future of Diabetes-Related Kidney Care Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. Accessed June 9, 2025. link] FDA Drug Shortages. Updated December 19, 2024. Accessed June 9, 2025.

Compounding 29

Compounding Pharmacy Technician Compounding Pharmacies Documentation 29

Pharmacy Times

JULY 1, 2025

Using data from the National Cancer Database, they performed a retrospective analysis on patients diagnosed with metastatic HR–/HER2+ breast cancer between January 2013 and December 2020. 031), and diagnosis between 2016 and 2018 (OR 1.93, P < 001) as well as 2019 and 2020 (1.88, P < 001). 3 Among the patients, approximately 75.8%

Pharmacy Technician 40

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunization 40

pharmaphorum

JUNE 17, 2025

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Drug Pricing 52

Pharmacy Times

JUNE 30, 2025

PCMA unanimous Supreme Court decision in 2020, which allowed states to regulate PBMs, the big health insurance companies and their PBM lobby have been barnstorming the country putting up one legal challenge after another. Douglas Hoey on the U.S.

Pharmacy Technician 26

Pharmacy Technician Community Pharmacies Compounding Pharmacies Immunization 26

Pharmacy Times

JUNE 18, 2025

PTCy recipients included those who received peripheral blood stem cells of haploidentical-related and mismatched unrelated donor transplants.

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Dosage Pharmacy Management 29

Pharmacy Times

JUNE 11, 2025

Image credit: marilyn barbone | stock.adobe.com Pharmacists as Key Players in Cardiovascular Treatment Plans Pharmacists are already crucial in managing medications for conditions like hypertension, hyperlipidemia, diabetes, and heart failure—all of which are significant risk factors for CVD. 2022;28(11):2238-2240. Fera T, Bluml BM, Ellis WM.

Pharmacy Technician 32

Pharmacy Technician Diabetes Compounding Pharmacies Grocery Stores 32

pharmaphorum

JUNE 17, 2025

Skip to main content Tuesday 17 June 2025 BlueSky linkedin youtube rss User account menu Subscribe Channels Channels Digital Market Access Oncology Patients R&D Sales & Marketing Spotlight on Content type Content type Digital -News -Views & Analysis -Deep Dive -Webinars -Podcasts -Video -White Papers -Event Market Access -News -Views & (..)

Diabetes 59

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 59

STAT

SEPTEMBER 23, 2022

Market share is often held up as the most relevant metric for the success of a biosimilar class. I believe there are other metrics, like cost savings or signs of greater patient access, that should also be used to define biosimilars’ successes or failures. the first biosimilar was launched in September 2015. In the U.S.,

Biosimilars 238

Biosimilars Diabetes Drug Pricing 238

pharmaphorum

JANUARY 28, 2021

It has been five years since the first biosimilar launched in United States market—marking the first steps in expanding access to innovative biologic-based treatments that help patients manage and treat difficult illnesses such as cancer, rheumatoid arthritis, and other life-altering diseases. million patients.

Biosimilars 119

Biosimilars Insurance Coverage and Processing Drug Pricing Diabetes 119

pharmaphorum

DECEMBER 21, 2020

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers – BMS’ buyout of Celegne and AbbVie’s acquisition of Allergan – accounted for almost 40% of total M&A deal values. Here we take a look at the biggest mergers and acquisitions of 2020 and what they might mean for the companies involved.

Biosimilars 126

Biosimilars Chemotherapy Immunization Immunity 126

pharmaphorum

SEPTEMBER 20, 2021

Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis’ Lucentis (ranibizumab) for leading causes of blindness, raising the prospect of a cheaper treatment option for US patients. billion respectively during 2020 as the pandemic reduced patient access to treatment.

Biosimilars 72

Biosimilars Labelling Diabetes 72

Drug Channels

JULY 29, 2020

In this issue: Pricing problems for diabetes treatments Controversy over Regeneron’s copay support Massachusetts concedes that coupons help some patients (but accumulators hurt) A 2020 update to my all-time favorite chart Plus, thoughtful perspectives on diversity from AmerisourceBergen CEO Steve Collis. d/b/a Drug Channels Institute.

Diabetes 52

Diabetes Biosimilars 52

Pharmaceutical Technology

JULY 15, 2022

In a budget change proposed in February and confirmed in May , California’s Department of Health Care Access and Information (HCAI) requested a one-time investment of $100 million for Newsom’s CalRx Biosimilar Insulin initiative. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin.

Biosimilars 131

Biosimilars Diabetes Documentation Packaging 131

pharmaphorum

JUNE 24, 2021

The original formulation has started to lose patent protection however, and a gaggle of drug developers – including Samsung Bioepis/Biogen, Hospira and Formycon/Bioeq – are already preparing to enter the US market with lower-cost biosimilars , with the first rivals expected to launch before year-end. billion in 2020 revenues.

Diabetes 95

Diabetes Biosimilars Drug Development 95

PharmaShots

FEBRUARY 1, 2023

Ximluci is expected to be available in the UK in 2023 The approval for Ximluci was granted through the EC decision reliance procedure, whereby the MHRA’s decision was based on the EC Ximluci was approved in the UK for wet AMD, DME, diabetic retinopathy, RVO, and visual impairment due to choroidal neovascularization in adults.

Biosimilars 40

Biosimilars Packaging Diabetes Hospitals 40

European Pharmaceutical Review

FEBRUARY 22, 2023

1 Used to treat a range of chronic diseases (eg, diabetes, rheumatoid arthritis, psoriasis, Crohn’s disease, haemophilia, etc), it is projected that the sales of biologics will rise from $380 billion in 2022 to $416 billion in 2023, and to almost $600 billion in 2027. Diabetes Therapy. The Business Research Company. 2019;10(2):437–49.

Biosimilars 105

Biosimilars Diabetes Immunization Immunity 105

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52

pharmaphorum

JUNE 1, 2021

While the discontinued studies don’t affect Beovu’s approved indication in wet AMD, the results add to concerns about ocular inflammation that were first voiced by the American Society of Retina Specialists (ASRS) in 2020 at a time when Novartis has been trying to restore confidence in the drug.

Biosimilars 66

Biosimilars Diabetes 66

pharmaphorum

MAY 21, 2021

It builds on the company’s four partnership projects: two with the generics and biosimilars firm Hikma, one with US biotech Inhibrix and another with an unnamed biosimilars partner. Eli Lilly, Novo Nordisk and there’s a group of biosimilar companies who already have a footprint in diabetes.”

Biosimilars 52

Biosimilars Diabetes 52

Putting Patients First Blog

JANUARY 27, 2025

The NHC recognizes that Medicare already covers AOMs for patients who are overweight and have comorbid conditions such as diabetes or cardiovascular disease. To further strengthen these efforts, the NHC recommends that CMS adopt additional measures to ensure broad access to generics, biosimilars, and other cost-effective treatments.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

Pharmaceutical Technology

MARCH 8, 2023

This recent price reduction to $35 has significant impact as rationing of insulin dosing has led to an increasing number of deaths among diabetics. These two insulin therapies have been off patent for about a decade but have a list price of about $500 for a pack of five injection pens and currently have limited competition from biosimilars.

Biosimilars 105

Biosimilars Diabetes 105

pharmaphorum

JANUARY 13, 2023

.” He added that people from low-income households and some racial and ethnic groups are disproportionately impacted by the practices, including Hispanic and Black people, who are much more likely to be diagnosed with diabetes than non-Hispanic white people – and much more likely to die as a result of complications.

Diabetes 105

Diabetes Drug Pricing Biosimilars 105

pharmaphorum

MAY 13, 2022

It has filed a lawsuit that accuses the drugmakers and pharmacy benefit managers Express Scripts, Caremark and OptumRx of conspiring to manipulate and inflate insulin prices in the state, inflating their profits and making the drugs unaffordable for many diabetics. Some companies are already taking steps to provide lower-cost products.

Diabetes 59

Diabetes Biosimilars Drug Pricing 59

pharmaphorum

MARCH 23, 2022

If passed, the Affordable Insulin Now Act would apply the cap across both private health insurance and Medicare plans, and according to Schumer would cut the cost of a 30-day supply of insulin for people with diabetes from a current range of $200 to $600 per person. Some companies are already taking steps to provide lower-cost insulin.

Diabetes 75

Diabetes Biosimilars Drug Pricing 75